Endocrine profiles and luteal function during GnRH-analogue/HMG therapy

We have found a significant improvement of pregnancy rates after pretreatment with an agonist of gonadotrophin releasing hormone (GnRH-a). The pregnancy rate in patients treated with HMG/HCG was 17% per patient and 5.5% per cycle, in patients treated with buserelin, 25% per patient and 15% per cycle...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human reproduction (Oxford) 1989-11, Vol.4 (8 Suppl), p.121-126
Hauptverfasser: Braendle, W, Lindner, C, Lichtenberg, V, Goepel, E, Bettendorf, G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 126
container_issue 8 Suppl
container_start_page 121
container_title Human reproduction (Oxford)
container_volume 4
creator Braendle, W
Lindner, C
Lichtenberg, V
Goepel, E
Bettendorf, G
description We have found a significant improvement of pregnancy rates after pretreatment with an agonist of gonadotrophin releasing hormone (GnRH-a). The pregnancy rate in patients treated with HMG/HCG was 17% per patient and 5.5% per cycle, in patients treated with buserelin, 25% per patient and 15% per cycle and in the triptorelin group 25% per patient and 22% per cycle. From 740 HMG/HCG cycles without GnRH-a only 66% were sufficient according to the analytical data. In 16% we found a premature LH discharge and in 18% an irregular LH fluctuation during stimulation. It is clear that gonadotrophin stimulation during pituitary suppression provokes a more intense ovarian reaction with respect to the number of follicles, as well as the endocrine activity. There are also some important practical advantages: ovarian stimulation can be started without any respect to a definite time of menstruation or of the cycle. Of further importance is the much greater flexibility in the timing of HCG administration. Finally, it will be favourable for all patients who need ovulation induction, especially for oocyte retrieval for IVF or GIFT, because no cycle has to be cancelled.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79434248</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79434248</sourcerecordid><originalsourceid>FETCH-LOGICAL-p121t-bad82e221d17b73b17790b6c2546333ae5d855f33a211902e94f6e0419c129373</originalsourceid><addsrcrecordid>eNotj8FKxDAURbNQxnH0E4Ss3BXzkjRpljKMHWFEEF2XtHkdK2lam2Yxf2_Bru5ZHC73XpEt46rIABTckNsYfxhbsFAbsuG5EBz0lpSH4IZm6gLScRrazmOkNjjq04zW0zaFZu6GQF1anDMtw8cxs8H64Zzw6fhW0vkbJzte7sh1a33E-zV35Ovl8Lk_Zqf38nX_fMpG4DBntXUFR87Bga61qEFrw2rV8FwqIYTF3BV53i7EAQzjaGSrkEkwDXAjtNiRx__eZe1vwjhXfRcb9N4GHFKstJFCclks4sMqprpHV41T19vpUq3PxR8IjVIv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79434248</pqid></control><display><type>article</type><title>Endocrine profiles and luteal function during GnRH-analogue/HMG therapy</title><source>Oxford University Press Journals Digital Archive legacy</source><source>MEDLINE</source><creator>Braendle, W ; Lindner, C ; Lichtenberg, V ; Goepel, E ; Bettendorf, G</creator><creatorcontrib>Braendle, W ; Lindner, C ; Lichtenberg, V ; Goepel, E ; Bettendorf, G</creatorcontrib><description>We have found a significant improvement of pregnancy rates after pretreatment with an agonist of gonadotrophin releasing hormone (GnRH-a). The pregnancy rate in patients treated with HMG/HCG was 17% per patient and 5.5% per cycle, in patients treated with buserelin, 25% per patient and 15% per cycle and in the triptorelin group 25% per patient and 22% per cycle. From 740 HMG/HCG cycles without GnRH-a only 66% were sufficient according to the analytical data. In 16% we found a premature LH discharge and in 18% an irregular LH fluctuation during stimulation. It is clear that gonadotrophin stimulation during pituitary suppression provokes a more intense ovarian reaction with respect to the number of follicles, as well as the endocrine activity. There are also some important practical advantages: ovarian stimulation can be started without any respect to a definite time of menstruation or of the cycle. Of further importance is the much greater flexibility in the timing of HCG administration. Finally, it will be favourable for all patients who need ovulation induction, especially for oocyte retrieval for IVF or GIFT, because no cycle has to be cancelled.</description><identifier>ISSN: 0268-1161</identifier><identifier>PMID: 2533217</identifier><language>eng</language><publisher>England</publisher><subject>Anovulation - blood ; Anovulation - drug therapy ; Anovulation - physiopathology ; Buserelin - therapeutic use ; Chorionic Gonadotropin - therapeutic use ; Estradiol - blood ; Female ; Follicle Stimulating Hormone - blood ; Gonadotropin-Releasing Hormone - analogs &amp; derivatives ; Gonadotropin-Releasing Hormone - therapeutic use ; Humans ; Luteal Phase - physiology ; Luteinizing Hormone - blood ; Luteolytic Agents - therapeutic use ; Menotropins - therapeutic use ; Ovulation Induction ; Progesterone - blood ; Testosterone - blood ; Triptorelin Pamoate</subject><ispartof>Human reproduction (Oxford), 1989-11, Vol.4 (8 Suppl), p.121-126</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2533217$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Braendle, W</creatorcontrib><creatorcontrib>Lindner, C</creatorcontrib><creatorcontrib>Lichtenberg, V</creatorcontrib><creatorcontrib>Goepel, E</creatorcontrib><creatorcontrib>Bettendorf, G</creatorcontrib><title>Endocrine profiles and luteal function during GnRH-analogue/HMG therapy</title><title>Human reproduction (Oxford)</title><addtitle>Hum Reprod</addtitle><description>We have found a significant improvement of pregnancy rates after pretreatment with an agonist of gonadotrophin releasing hormone (GnRH-a). The pregnancy rate in patients treated with HMG/HCG was 17% per patient and 5.5% per cycle, in patients treated with buserelin, 25% per patient and 15% per cycle and in the triptorelin group 25% per patient and 22% per cycle. From 740 HMG/HCG cycles without GnRH-a only 66% were sufficient according to the analytical data. In 16% we found a premature LH discharge and in 18% an irregular LH fluctuation during stimulation. It is clear that gonadotrophin stimulation during pituitary suppression provokes a more intense ovarian reaction with respect to the number of follicles, as well as the endocrine activity. There are also some important practical advantages: ovarian stimulation can be started without any respect to a definite time of menstruation or of the cycle. Of further importance is the much greater flexibility in the timing of HCG administration. Finally, it will be favourable for all patients who need ovulation induction, especially for oocyte retrieval for IVF or GIFT, because no cycle has to be cancelled.</description><subject>Anovulation - blood</subject><subject>Anovulation - drug therapy</subject><subject>Anovulation - physiopathology</subject><subject>Buserelin - therapeutic use</subject><subject>Chorionic Gonadotropin - therapeutic use</subject><subject>Estradiol - blood</subject><subject>Female</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Gonadotropin-Releasing Hormone - analogs &amp; derivatives</subject><subject>Gonadotropin-Releasing Hormone - therapeutic use</subject><subject>Humans</subject><subject>Luteal Phase - physiology</subject><subject>Luteinizing Hormone - blood</subject><subject>Luteolytic Agents - therapeutic use</subject><subject>Menotropins - therapeutic use</subject><subject>Ovulation Induction</subject><subject>Progesterone - blood</subject><subject>Testosterone - blood</subject><subject>Triptorelin Pamoate</subject><issn>0268-1161</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotj8FKxDAURbNQxnH0E4Ss3BXzkjRpljKMHWFEEF2XtHkdK2lam2Yxf2_Bru5ZHC73XpEt46rIABTckNsYfxhbsFAbsuG5EBz0lpSH4IZm6gLScRrazmOkNjjq04zW0zaFZu6GQF1anDMtw8cxs8H64Zzw6fhW0vkbJzte7sh1a33E-zV35Ovl8Lk_Zqf38nX_fMpG4DBntXUFR87Bga61qEFrw2rV8FwqIYTF3BV53i7EAQzjaGSrkEkwDXAjtNiRx__eZe1vwjhXfRcb9N4GHFKstJFCclks4sMqprpHV41T19vpUq3PxR8IjVIv</recordid><startdate>198911</startdate><enddate>198911</enddate><creator>Braendle, W</creator><creator>Lindner, C</creator><creator>Lichtenberg, V</creator><creator>Goepel, E</creator><creator>Bettendorf, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>198911</creationdate><title>Endocrine profiles and luteal function during GnRH-analogue/HMG therapy</title><author>Braendle, W ; Lindner, C ; Lichtenberg, V ; Goepel, E ; Bettendorf, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p121t-bad82e221d17b73b17790b6c2546333ae5d855f33a211902e94f6e0419c129373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Anovulation - blood</topic><topic>Anovulation - drug therapy</topic><topic>Anovulation - physiopathology</topic><topic>Buserelin - therapeutic use</topic><topic>Chorionic Gonadotropin - therapeutic use</topic><topic>Estradiol - blood</topic><topic>Female</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Gonadotropin-Releasing Hormone - analogs &amp; derivatives</topic><topic>Gonadotropin-Releasing Hormone - therapeutic use</topic><topic>Humans</topic><topic>Luteal Phase - physiology</topic><topic>Luteinizing Hormone - blood</topic><topic>Luteolytic Agents - therapeutic use</topic><topic>Menotropins - therapeutic use</topic><topic>Ovulation Induction</topic><topic>Progesterone - blood</topic><topic>Testosterone - blood</topic><topic>Triptorelin Pamoate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Braendle, W</creatorcontrib><creatorcontrib>Lindner, C</creatorcontrib><creatorcontrib>Lichtenberg, V</creatorcontrib><creatorcontrib>Goepel, E</creatorcontrib><creatorcontrib>Bettendorf, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Braendle, W</au><au>Lindner, C</au><au>Lichtenberg, V</au><au>Goepel, E</au><au>Bettendorf, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endocrine profiles and luteal function during GnRH-analogue/HMG therapy</atitle><jtitle>Human reproduction (Oxford)</jtitle><addtitle>Hum Reprod</addtitle><date>1989-11</date><risdate>1989</risdate><volume>4</volume><issue>8 Suppl</issue><spage>121</spage><epage>126</epage><pages>121-126</pages><issn>0268-1161</issn><abstract>We have found a significant improvement of pregnancy rates after pretreatment with an agonist of gonadotrophin releasing hormone (GnRH-a). The pregnancy rate in patients treated with HMG/HCG was 17% per patient and 5.5% per cycle, in patients treated with buserelin, 25% per patient and 15% per cycle and in the triptorelin group 25% per patient and 22% per cycle. From 740 HMG/HCG cycles without GnRH-a only 66% were sufficient according to the analytical data. In 16% we found a premature LH discharge and in 18% an irregular LH fluctuation during stimulation. It is clear that gonadotrophin stimulation during pituitary suppression provokes a more intense ovarian reaction with respect to the number of follicles, as well as the endocrine activity. There are also some important practical advantages: ovarian stimulation can be started without any respect to a definite time of menstruation or of the cycle. Of further importance is the much greater flexibility in the timing of HCG administration. Finally, it will be favourable for all patients who need ovulation induction, especially for oocyte retrieval for IVF or GIFT, because no cycle has to be cancelled.</abstract><cop>England</cop><pmid>2533217</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0268-1161
ispartof Human reproduction (Oxford), 1989-11, Vol.4 (8 Suppl), p.121-126
issn 0268-1161
language eng
recordid cdi_proquest_miscellaneous_79434248
source Oxford University Press Journals Digital Archive legacy; MEDLINE
subjects Anovulation - blood
Anovulation - drug therapy
Anovulation - physiopathology
Buserelin - therapeutic use
Chorionic Gonadotropin - therapeutic use
Estradiol - blood
Female
Follicle Stimulating Hormone - blood
Gonadotropin-Releasing Hormone - analogs & derivatives
Gonadotropin-Releasing Hormone - therapeutic use
Humans
Luteal Phase - physiology
Luteinizing Hormone - blood
Luteolytic Agents - therapeutic use
Menotropins - therapeutic use
Ovulation Induction
Progesterone - blood
Testosterone - blood
Triptorelin Pamoate
title Endocrine profiles and luteal function during GnRH-analogue/HMG therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T05%3A39%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endocrine%20profiles%20and%20luteal%20function%20during%20GnRH-analogue/HMG%20therapy&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=Braendle,%20W&rft.date=1989-11&rft.volume=4&rft.issue=8%20Suppl&rft.spage=121&rft.epage=126&rft.pages=121-126&rft.issn=0268-1161&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E79434248%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79434248&rft_id=info:pmid/2533217&rfr_iscdi=true